文献速递血栓与止血

儿童直接口服抗凝药治疗静脉血栓栓塞试验的设计、方法学与患者人群特征的系统分析

Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatment.
PubMed 文献 · J Thromb Haemost · 2025-01-09

该研究系统检索MEDLINE、EMBASE、Cochrane图书馆和ClinicalTrials.gov(2002年1月至2022年12月),纳入5项已发表研究和2项未发表试验数据,评估儿童直接口服抗凝药治疗静脉血栓栓塞试验的设计与方法学。所有试验均对设计或方法学进行了修改,注册信息与最终发表研究之间存在差异,提示可行性挑战。

要点

  • 所有儿童直接口服抗凝药试验均对设计或方法学进行了修改,注册信息与最终发表研究存在差异。
  • 所有试验均存在入选标准修改、样本量变化、年轻患者招募困难及入组人群与临床目标人群不匹配。
  • 结局报告差异常见,尤其是次要终点。

核心结论

  • 儿童直接口服抗凝药试验经历了可行性挑战,导致设计或方法学修改。

研究设计与样本

  • 系统检索MEDLINE、EMBASE、Cochrane图书馆和ClinicalTrials.gov(2002年1月至2022年12月),纳入报告儿童急性静脉血栓栓塞治疗用直接口服抗凝药干预性试验结果的研究及其设计论文,共5项已发表研究和2项未发表试验数据。

主要发现

  • 所有试验均对设计或方法学进行了修改,且试验注册信息与最终发表研究之间存在差异,提示可行性挑战。
  • 所有试验均识别出入选标准修改、样本量变化、年轻患者招募困难以及入组人群与临床目标人群不匹配。
  • 结局报告差异常见,尤其是次要终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pediatric direct oral anticoagulation (DOAC) trials provide an opportunity to evaluate and characterize challenges in their design and execution to inform future antithrombotic trials. OBJECTIVES: To perform a systematic review of pediatric DOAC trials for the treatment of venous thromboembolism to critically appraise their methodology and understand the feasibility and challenges. METHODS: We performed a systematic search of MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov (January 2002 to December 2022). Studies reporting the results of interventional trials of a DOAC for the treatment of acute venous thromboembolism in children and their respective design papers were included. Trial registration information was reviewed in ClinicalTrials.gov. Discrepancies in study design, targeted populations, sample size, and analyses between planned and actual trial conduct were examined qualitatively. RESULTS: Five published studies and unpublished data for 2 additional trials were included. All trials had modifications to their design or methodology and discrepancies between the trial's registration and the final published study, suggesting feasibility challenges. Modifications to the eligibility criteria, changes in sample size, challenges with the recruitment of younger patients, and an enrolled population not matching the clinical target population were identified for all trials. Discrepancies in outcome reporting, particularly for secondary endpoints, were also common. CONCLUSION: DOAC trials experienced feasibility challenges that led to design or methodology modifications. Future pediatric antithrombotic trials will need to be adaptive in their design, prioritize enrollment of younger children and input from clinicians providing care to target populations, ensure that enrolled populations match the clinical population, and select clinically meaningful endpoints.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Betensky M, Albisetti M, Biss T, et al. Systematic analysis of the design, methodology, and patient population characteristics of the pediatric direct oral anticoagulant trials of venous thromboembolism treatment. J Thromb Haemost. 2025. PMID: 39798923. doi:10.1016/j.jtha.2024.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。